Washington, D.C., August 9, 2024 – The ERISA Industry Committee (“ERIC”) this week submitted comments to Assemblymember Buffy Wicks (D-Oakland) and the California State Assembly Appropriations Committee regarding the applicability and enforceability of SB 966 to self-insured health benefit plans governed by the federal Employee Retirement Income Security Act of 1974 (“ERISA”).
Topic Archives:
ERIC Health Care Highlights: Pharmacy Benefit Survey; DOL EAC – Member Action Needed; and More
Sorry, but you do not have permission to view this content.
ERIC Health Care Highlights: ERIC’s Fall Virtual Policy Conference; Survey Responses Needed; and More
Sorry, but you do not have permission to view this content.
RIC Health Care Highlights: ERIC’s Fall Virtual Policy Conference; Claims Procedures Survey; and More
Sorry, but you do not have permission to view this content.
ERIC Health Care Highlights: DOL EAC Nominations; PBM Oversight Hearing; and More
Sorry, but you do not have permission to view this content.
P4ESC Opposes Efforts to Tax Employees on the Value of Their Health Coverage
WASHINGTON, July 17, 2024 – The Partnership for Employer-Sponsored Coverage (P4ESC) today underlined opposition to proposals made by the Paragon Health Institute and others to cap the individual income tax exclusion for employer-sponsored coverage.
ERIC Health Care Highlights: FTC Staff Report on PBMs, Congress to the Agencies – Chevron, Problematic Model State PBM Legislation, P4ESC Letter, More
Today we’ll discuss: (1)FTC Staff Report on PBMs, (2)Congress to the Agencies – Chevron, (3)Problematic Model State PBM Legislation(4)P4ESC Tax Exclusion Advocacy, (5)Site Act Advocacy, (6)Comments on Double Patents, (7)Republican Platform, (8)Spring Unified Agenda, (9) What We’re Reading.
The ERISA Industry Committee Praises U.S. Patent and Trademark Office Proposed Rule to Reform Patent Process, Improve Competition, and Make Prescription Drugs More Affordable
The ERISA Industry Committee (ERIC) today praised a proposed rule by the U.S. Patent and Trademark Office (USPTO) to increase competition in the prescription drug markets, boosting the availability of affordable biosimilar drugs by reforming patent policies. The new rule would crack down on “terminal disclaimers,” a strategy used by branded drug manufacturers to stave off competition for much longer than Congress intended.
ERIC Health Care Highlights: Programming Reminders; CBO Report; and More!
Sorry, but you do not have permission to view this content.
The ERISA Industry Committee Urges the Texas AG to Recognize the Limits of Texas State Authority
Washington, D.C., June 18, 2024 – The ERISA Industry Committee (“ERIC”) yesterday submitted comments in response to a request for opinion sent to Texas Attorney General Ken Paxton by Senator Charles Schwertner regarding the applicability and enforceability of two Texas state laws, HB 1763 and HB 1919, to self-funded health benefit plans governed by the federal Employee Retirement Income Security Act of 1974 (“ERISA”).